"Casting a wide net" with its phase I trial testing MRX34, Mirna Therapeutics Inc. raked in $41.8 million by way of a series D financing that will enable a phase II experiment in the first half of next year, in a cancer indication yet to be decided upon, CEO Paul Lammers told BioWorld Today.